[EN] IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY [FR] IMAGERIE D'HISTONE DÉSACÉTYLASES AU MOYEN D'UN RADIOTRACEUR À L'AIDE DE LA TOMOGRAPHIE PAR ÉMISSION DE POSITRONS
[EN] CARBORANE-BASED HISTONE DEACETYLASE (HDAC) INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE (HDAC) À BASE DE CARBORANE
申请人:UNIV CALIFORNIA
公开号:WO2020117976A1
公开(公告)日:2020-06-11
The present disclosure provides compounds and compositions capable of treating cancer, a disease of the central nervous system, and an inflammatory autoimmune disease, and methods of use thereof.
[EN] IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY<br/>[FR] IMAGERIE D'HISTONE DÉSACÉTYLASES AU MOYEN D'UN RADIOTRACEUR À L'AIDE DE LA TOMOGRAPHIE PAR ÉMISSION DE POSITRONS
申请人:GEN HOSPITAL CORP
公开号:WO2015058106A1
公开(公告)日:2015-04-23
Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.
Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plama ratio of 20: 1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided.
Imaging histone deacetylases with a radiotracer using positron emission tomography
申请人:THE GENERAL HOSPITAL CORPORATION
公开号:US10188756B2
公开(公告)日:2019-01-29
Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.